Kogan T P, Dupré B, Bui H, McAbee K L, Kassir J M, Scott I L, Hu X, Vanderslice P, Beck P J, Dixon R A
Department of Chemistry & Biophysics, Texas Biotechnology Corporation, Houston 77030, USA.
J Med Chem. 1998 Mar 26;41(7):1099-111. doi: 10.1021/jm9704917.
Reports of a high-affinity ligand for E-selectin, sialyl di-Lewis(x) (sLe(x)Le(x), 1), motivated us to incorporate modifications to previously reported biphenyl-based inhibitors that would provide additional interactions with the protein. These compounds were assayed for the ability to inhibit the binding of sialyl Lewis(x) (sLe(x), 2) bearing HL-60 cells to E-, P-, and L-selectin fusion proteins. We report that dimeric or trimeric compounds containing multiple components of simple nonoligosaccharide selectin antagonists inhibit sLe(x)-dependent binding with significantly enhanced potency over the monomeric compound. The enhanced potency is consistent with additional binding interactions within a single selectin lectin domain; however, multivalent interaction with multiple lectin domains as a possible alternative cannot be ruled out. Compound 15e (TBC1269) showed optimal in vitro activity from this class of antagonists and is currently under development for use in the treatment of asthma.
针对E-选择素的一种高亲和力配体——唾液酸化二岩藻糖基路易斯x(sLe(x)Le(x),1)的报道,促使我们对先前报道的基于联苯的抑制剂进行修饰,使其与该蛋白产生更多相互作用。对这些化合物抑制携带HL-60细胞的唾液酸化路易斯x(sLe(x),2)与E-、P-和L-选择素融合蛋白结合的能力进行了测定。我们报道,含有简单非寡糖选择素拮抗剂多个组分的二聚体或三聚体化合物,抑制sLe(x)依赖性结合的效力比单体化合物显著增强。效力增强与单个选择素凝集素结构域内的额外结合相互作用一致;然而,与多个凝集素结构域的多价相互作用作为一种可能的替代情况也不能排除。化合物15e(TBC1269)在此类拮抗剂中显示出最佳的体外活性,目前正处于用于治疗哮喘的研发阶段。